A whole-genome RNA interference screen for human cell factors affecting Myxoma virus replication

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4623-4641

  Teferi, Wondimagegnehu M ^a   Dodd, Kristopher ^a   Maranchuk, Rob ^a   Favis, Nicole ^a   Evans, David H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 PHOSPHOFRUCTOKINASE; BETA CATENIN; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; DEOXYGLUCOSE; DNA PRIMASE; GENOMIC RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PROTEASOME;

ANAEROBIC GLYCOLYSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL METABOLISM; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE CLUSTER; GENE IDENTIFICATION; GENE LIBRARY; GENE POOL; GENE TARGETING; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; KINASE GENE; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHOSPHATASE GENE; PRIORITY JOURNAL; RNA INTERFERENCE; RNA STABILITY; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS REPLICATION; WNT SIGNALING PATHWAY;

CELL LINE; GENOME, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MOLECULAR BIOLOGY; MYXOMA VIRUS; RNA INTERFERENCE; VIRUS REPLICATION;

MYXOMA VIRUS; ORYCTOLAGUS CUNICULUS;

EID: 84875769526     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02617-12     Document Type: Article

References (127)

1. Fenner F. 2000. Adventures with poxviruses of vertebrates. FEMS Microbiol. Rev. 24:123-133.
2. Fenner F, Fantini B. 1999. Biological control of vertebrate pests: the history of myxomatosis-an experiment in evolution. CABI Publishing, New York, NY.
3. Kerr PJ. 2012. Myxomatosis in Australia and Europe: a model for emerging infectious diseases. Antiviral Res. 93:387-415.
4. Werden SJ, Barrett JW, Wang G, Stanford MM, McFadden G. 2007. M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J. Virol. 81: 2340-2348.
5. Opgenorth A, Nation N, Graham K, McFadden G. 1993. Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology 192:701-709.
6. Wang F, Ma Y, Barrett JW, Gao X, Loh J, Barton E, Virgin HW, McFadden G. 2004. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5:1266-1274.
7. Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW, Lees-Miller SP, Mori Y, Rahman MM, McFadden G, Johnston RN. 2010. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29:3990-3996.
8. Wang F, Barrett JW, Ma Y, Dekaban GA, McFadden G. 2009. Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J. Virol. 83:5928-5932.
9. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas A, McFadden G. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
10. Spiesschaert B, McFadden G, Hermans K, Nauwynck H, Van de Walle GR. 2011. The current status and future directions of myxoma virus, a master in immune evasion. Vet. Res. 42:76.
11. Werden SJ, McFadden G. 2008. The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim. Biophys. Acta 1784:228-237.
12. Cameron C, Hota-Mitchell S, Chen L, Barrett J, Cao JX, Macaulay C, Willer D, Evans D, McFadden G. 1999. The complete DNA sequence of myxoma virus. Virology 264:298-318.
13. Duteyrat JL, Gelfi J, Bertagnoli S. 2006. Ultrastructural study of myxoma virus morphogenesis. Arch. Virol. 151:2161-2180.
14. Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, Neff C, Dufford M, Lanchbury JS, Labaer J, McFadden G. 2009. Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J. Proteome Res. 8:4311-4318.
15. Lin YC, Li J, Irwin CR, Jenkins H, DeLange L, Evans DH. 2008. Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly. J. Virol. 82:5922-5932.
16. Willer DO, McFadden G, Evans DH. 1999. The complete genome sequence of Shope (rabbit) fibroma virus. Virology 264:319-343.
17. Gammon DB, Gowrishankar B, Duraffour S, Andrei G, Upton C, Evans DH. 2010. Vaccinia virus-encoded ribonucleotide reductase sub- units are differentially required for replication and pathogenesis. PLoS Pathog. 6:e1000984. doi:10.1371/journal.ppat.1000984.
18. Reichard P. 1988. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. 57:349-374.
19. Cherry S, Doukas T, Armknecht S, Whelan S, Wang H, Sarnow P, Perrimon N. 2005. Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. Genes Dev. 19:445-452.
20. Hao L, Sakurai A, Watanabe T, Sorensen E, Nidom CA, Newton MA, Ahlquist P, Kawaoka Y. 2008. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature 454:890-893.
21. Sessions OM, Barrows NJ, Souza-Neto JA, Robinson TJ, Hershey CL, Rodgers MA, Ramirez JL, Dimopoulos G, Yang PL, Pearson JL, Garcia-Blanco MA. 2009. Discovery of insect and human dengue virus host factors. Nature 458:1047-1050.
22. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ, Lieberman J, Elledge SJ. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926.
23. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, Espeseth AS. 2008. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495-504.
24. Krishnan MN, Ng A, Sukumaran B, Gilfoy FD, Uchil PD, Sultana H, Brass AL, Adametz R, Tsui M, Qian F, Montgomery RR, Lev S, Mason PW, Koski RA, Elledge SJ, Xavier RJ, Agaisse H, Fikrig E. 2008. RNA interference screen for human genes associated with West Nile virus infection. Nature 455:242-245.
25. Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. 2009. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. U. S. A. 106:16410-16415.
26. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. 2009. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 5:298-307.
27. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, Hess S, Maurer AP, Muller E, Wolff T, Rudel T, Meyer TF. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463: 818-822.
28. Panda D, Das A, Dinh PX, Subramaniam S, Nayak D, Barrows NJ, Pearson JL, Thompson J, Kelly DL, Ladunga I, Pattnaik AK. 2011. RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses. Proc. Natl. Acad. Sci. U. S. A. 108:19036-19041.
29. Moser TS, Jones RG, Thompson CB, Coyne CB, Cherry S. 2010. A kinome RNAi screen identified AMPK as promoting poxvirus entry through the control of actin dynamics. PLoS Pathog. 6:e1000954. doi:10 .1371/journal.ppat.1000954.
30. Goff SP. 2008. Knockdown screens to knockout HIV-1. Cell 135:417-420.
31. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK. 2008. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60.
32. Yeung ML, Houzet L, Yedavalli VS, Jeang KT. 2009. A genome-wide short hairpin RNA screening of Jurkat T-cells for human proteins contributing to productive HIV-1 replication. J. Biol. Chem. 284:19463-19473.
33. Beller M, Sztalryd C, Southall N, Bell M, Jackle H, Auld DS, Oliver B. 2008. COPI complex is a regulator of lipid homeostasis. PLoS Biol. 6:e292. doi:10.1371/journal.pbio.0060292.
34. Guo Y, Walther TC, Rao M, Stuurman N, Goshima G, Terayama K, Wong JS, Vale RD, Walter P, Farese RV. 2008. Functional genomic screen reveals genes involved in lipid-droplet formation and utilization. Nature 453:657-661.
35. Mohr S, Bakal C, Perrimon N. 2010. Genomic screening with RNAi: results and challenges. Annu. Rev. Biochem. 79:37-64.
36. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A. 2006. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3:199-204.
37. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:635-637.
38. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS. 2006. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-1187.
39. Qiu S, Adema CM, Lane T. 2005. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33:1834-1847.
40. Sigoillot FD, Lyman S, Huckins JF, Adamson B, Chung E, Quattrochi B, King RW. 2012. A bioinformatics method identifies prominent offtargeted transcripts in RNAi screens. Nat. Methods 9:363-366.
41. Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, Barrionuevo LS, Lichter P, Mertens D. 2008. Off-target effects of siRNA specific for GFP.BMCMol. Biol. 9:60. doi:10.1186/1471-2199-9-60.
42. Opgenorth A, Graham K, Nation N, Strayer D, McFadden G. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 66:4720-4731.
43. Parsons BD, Schindler A, Evans DH, Foley E. 2009. A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay. PLoS One 4:e8471. doi:10.1371/journal.pone.0008471.
44. Lundholm L, Mohme-Lundholm E, Vamos N. 1963. Lactic acid assay with L(+)lactic acid dehydrogenase from rabbit muscle. Acta Physiol. Scand. 58:243-249.
45. Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P. 2004. Comparison of alamar blue and MTT assays for high throughput screening. Toxicol. In Vitro 18:703-710.
46. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE. 2009. Statistical methods for analysis of high-throughput RNA interference screens. Nat. Methods 6:569-575.
47. Zhang XD, Ferrer M, Espeseth AS, Marine SD, Stec EM, Crackower MA, Holder DJ, Heyse JF, Strulovici B. 2007. The use of strictly standardized mean difference for hit selection in primary RNA interference high-throughput screening experiments. J. Biomol. Screen. 12:497-509.
48. Zhang XD, Lacson R, Yang R, Marine SD, McCampbell A, Toolan DM, Hare TR, Kajdas J, Berger JP, Holder DJ, Heyse JF, Ferrer M. 2010. The use of SSMD-based false discovery and false nondiscovery rates in genome-scale RNAi screens. J. Biomol. Screen. 15:1123-1131.
49. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A. 2003. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13:2129-2141.
50. Huang da W, Sherman BT, Lempicki RA. 2009. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1-13.
51. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
52. Luc PV, Tempst P. 2004. PINdb: a database of nuclear protein complexes from human and yeast. Bioinformatics 20:1413-1415.
53. Cailleau R, Young R, Olive M, Reeves WJ, Jr. 1974. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661-674.
54. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT. 1997. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 4:317-322.
55. Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17:5948-5963.
56. Wang G, Barrett JW, Stanford M, Werden SJ, Johnston JB, Gao X, Sun M, Cheng JQ, McFadden G. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. U. S. A. 103: 4640-4645.
57. Boutros M, Bras LP, Huber W. 2006. Analysis of cell-based RNAi screens. Genome Biol. 7:R66. doi:10.1186/gb-2006-7-7-r66.
58. Bonvini P, Zorzi E, Basso G, Rosolen A. 2007. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 21:838-842.
59. Satheshkumar PS, Anton LC, Sanz P, Moss B. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
60. Teale A, Campbell S, Van Buuren N, Magee WC, Watmough K, Couturier B, Shipclark R, Barry M. 2009. Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication. J. Virol. 83:2099-2108.
61. Levine AJ, Puzio-Kuter AM. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340-1344.
62. Gatenby RA, Gillies RJ. 2004. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4:891-899.
63. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. 2001. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 15:1406-1418.
64. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. 2002. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta 1555:14-20.
65. Wallace DC. 2005. Mitochondria and cancer: Warburg addressed. Cold Spring Harbor Symp. Quant Biol. 70:363-374.
66. Kun E, Smith MH. 1950. Effect of infectious myxoma virus on glycolysis of chorioallantoic membrane of chick embryo. Proc. Soc. Exp. Biol. Med. 73:628-631.
67. Weber G. 1977. Enzymology of cancer cells (second of two parts). N. Engl. J. Med. 296:541-551.
68. Van Schaftingen E, Hers HG. 1981. Phosphofructokinase 2: the enzyme that forms fructose 2,6-bisphosphate from fructose 6-phosphate and ATP. Biochem. Biophys. Res. Commun. 101:1078-1084.
69. Van Schaftingen E, Hue L, Hers HG. 1980. Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. Biochem. J. 192:897-901.
70. Van Schaftingen E, Jett MF, Hue L, Hers HG. 1981. Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors. Proc. Natl. Acad. Sci. U. S. A. 78:3483-3486.
71. Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T. 2005. Phosphorylation of the 6-phosphofructo- 2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin. Cancer Res. 11:5784-5792.
72. Kyriakis JM, Avruch J. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807-869.
73. Sears RC, Nevins JR. 2002. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277:11617-11620.
74. Brown JP, Twardzik DR, Marquardt H, Todaro GJ. 1985. Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature 313:491-492.
75. Twardzik DR, Brown JP, Ranchalis JE, Todaro GJ, Moss B. 1985. Vaccinia virus-infected cells release a novel polypeptide functionally related to transforming and epidermal growth factors. Proc. Natl. Acad. Sci. U. S. A. 82:5300-5304.
76. Chang W, Upton C, Hu SL, Purchio AF, McFadden G. 1987. The genome of Shope fibroma virus, a tumorigenic poxvirus, contains a growth factor gene with sequence similarity to those encoding epidermal growth factor and transforming growth factor alpha. Mol. Cell. Biol. 7:535-540.
77. Upton C, Macen JL, McFadden G. 1987. Mapping and sequencing of a gene from myxoma virus that is related to those encoding epidermal growth factor and transforming growth factor alpha. J. Virol. 61:1271-1275.
78. Andrade AA, Silva PN, Pereira AC, De Sousa LP, Ferreira PC, Gazzinelli RT, Kroon EG, Ropert C, Bonjardim CA. 2004. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem. J. 381:437-446.
79. Schweneker M, Lukassen S, Spath M, Wolferstatter M, Babel E, Brinkmann K, Wielert U, Chaplin P, Suter M, Hausmann J. 2012. The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence. J. Virol. 86:2323-2336.
80. Wang F, Gao X, Barrett JW, Shao Q, Bartee E, Mohamed MR, Rahman M, Werden S, Irvine T, Cao J, Dekaban GA, McFadden G. 2008. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog. 4:e1000099. doi:10.1371/journal.ppat.1000099.
81. Lonne GK, Masoumi KC, Lennartsson J, Larsson C. 2009. Protein kinase C supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J. Biol. Chem. 284:33456-33465.
82. Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW. 2010. Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res. 70:4912-4921.
83. Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R, Nurcombe V, Le Bourhis X, Hondermarck H. 2008. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 68: 346-351.
84. Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM, Cook SJ. 2008. DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell. Signal. 20:836-843.
85. Mandl M, Slack DN, Keyse SM. 2005. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol. Cell. Biol. 25:1830-1845.
86. Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. 2002. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep. 3:1201-1208.
87. Mingo-Sion AM, Marietta PM, Koller E, Wolf DM, Van Den Berg CL. 2004. Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene 23:596-604.
88. Wang L, Pan Y, Dai JL. 2004. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 23:5978-5985.
89. Nezu J, Oku A, Jones MH, Shimane M. 1997. Identification of two novel human putative serine/threonine kinases, VRK1 and VRK2, with structural similarity to vaccinia virus B1R kinase. Genomics 45:327-331.
90. Nichols RJ, Wiebe MS, Traktman P. 2006. The vaccinia-related kinases phosphorylate the N= terminus of BAF, regulating its interaction with DNA and its retention in the nucleus. Mol. Biol. Cell 17:2451-2464.
91. Fernandez IF, Blanco S, Lozano J, Lazo PA. 2010. VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer. Mol. Cell. Biol. 30:4687-4697.
92. Blanco S, Sanz-Garcia M, Santos CR, Lazo PA. 2008. Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein. PLoS One 3:e1660. doi:10.1371/journal .pone.0001660.
93. Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G. 2007. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J. Virol. 81:1251-1260.
94. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ. 2001. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8:249-258.
95. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, Deng X, Chen L, Kim CC, Lau S, Somlo G, Yen Y. 2011. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30:4437-4446.
96. Ke J, Zhang C, Harikumar KG, Zylstra-Diegel CR, Wang L, Mowry LE, Miller LJ, Williams BO, Xu HE. 2012. Modulation of beta-catenin signaling by glucagon receptor activation. PLoS One 7:e33676. doi:10 .1371/journal.pone.0033676.
97. Pendas-Franco N, Garcia JM, Pena C, Valle N, Palmer HG, Heinaniemi M, Carlberg C, Jimenez B, Bonilla F, Munoz A, Gonzalez-Sancho JM. 2008. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1α,25-dihydroxyvitamin D3. Oncogene 27: 4467-4477.
98. Shapiro L, Weis WI. 2009. Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol. 1:a003053. doi:10.1101 /cshperspect.a003053.
99. Sumi T, Matsumoto K, Takai Y, Nakamura T. 1999. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42- activated LIM-kinase 2. J. Cell Biol. 147:1519-1532.
100. Carramusa L, Ballestrem C, Zilberman Y, Bershadsky AD. 2007. Mammalian diaphanous-related formin Dia1 controls the organization of E-cadherin-mediated cell-cell junctions. J. Cell Sci. 120:3870-3882.
101. Irwin CR, Evans DH. 2012. Modulation of the myxoma virus plaque phenotype by vaccinia virus F11 protein. J. Virol. 86:7167-7179.
102. Johnston JB, Wang G, Barrett JW, Nazarian SH, Colwill K, Moran M, McFadden G. 2005. Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1. J. Virol. 79:10750-10763.
103. Chen HZ, Tsai SY, Leone G. 2009. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9:785-797.
104. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF, Firestone GL. 1998. Indole-3-carbinol inhibits the expression of cyclindependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J. Biol. Chem. 273:3838-3847.
105. Bell SP, Dutta A. 2002. DNA replication in eukaryotic cells. Annu. Rev. Biochem. 71:333-374.
106. Sherr CJ. 1995. D-type cyclins. Trends Biochem. Sci. 20:187-190.
107. Nigg EA. 1996. Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Curr. Opin. Cell Biol. 8:312-317.
108. Gao G, Bracken AP, Burkard K, Pasini D, Classon M, Attwooll C, Sagara M, Imai T, Helin K, Zhao J. 2003. NPAT expression is regulated by E2F and is essential for cell cycle progression. Mol. Cell. Biol. 23:2821-2833.
109. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, Osada H. 2004. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc. Natl. Acad. Sci. U. S. A. 101:4419-4424.
110. Negrini M, Sabbioni S, Haldar S, Possati L, Castagnoli A, Corallini A, Barbanti-Brodano G, Croce CM. 1994. Tumor and growth suppression of breast cancer cells by chromosome 17-associated functions. Cancer Res. 54:1818-1824.
111. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. 2007. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11:175-189.
112. Liaw H, Lee D, Myung K. 2011. DNA-PK-dependent RPA2 hyperphosphorylation facilitates DNA repair and suppresses sister chromatid exchange. PLoS One 6:e21424. doi:10.1371/journal.pone.0021424.
113. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. 2006. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 5:2543-2547.
114. Sorensen CS, Syljuasen RG. 2012. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 40:477-486.
115. Lee HJ, Hwang HI, Jang YJ. 2010. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle 9:2389-2398.
116. Lobjois V, Froment C, Braud E, Grimal F, Burlet-Schiltz O, Ducommun B, Bouche JP. 2011. Study of the docking-dependent PLK1 phosphorylation of the CDC25B phosphatase. Biochem. Biophys. Res. Commun. 410:87-90.
117. Lan W, Cleveland DW. 2010. A chemical tool box defines mitotic and interphase roles for Mps1 kinase. J. Cell Biol. 190:21-24.
118. Lara-Gonzalez P, Scott MI, Diez M, Sen O, Taylor SS. 2011. BubR1 blocks substrate recruitment to the APC/C in a KEN-box-dependent manner. J. Cell Sci. 124:4332-4345.
119. Lee SH, Sterling H, Burlingame A, McCormick F. 2008. Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev. 22:2926-2931.
120. Pyronnet S, Dostie J, Sonenberg N. 2001. Suppression of capdependent translation in mitosis. Genes Dev. 15:2083-2093.
121. Barford D. 2011. Structural insights into anaphase-promoting complex function and mechanism. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366: 3605-3624.
122. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. 2009. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R77. doi:10.1186/bcr2419.
123. Frick DN, Richardson CC. 2001. DNA primases. Annu. Rev. Biochem. 70:39-80.
124. Tseng BY, Ahlem CN. 1982. DNA primase activity from human lymphocytes. Synthesis of oligoribonucleotides that prime DNA synthesis. J. Biol. Chem. 257:7280-7283.
125. Yagura T, Kozu T, Seno T, Saneyoshi M, Hiraga S, Nagano H. 1983. Novel form of DNA polymerase alpha associated with DNA primase activity of vertebrates. Detection with mouse stimulating factor. J. Biol. Chem. 258:13070-13075.
126. Griffiths DJ, Liu VF, Nurse P, Wang TS. 2001. Role of fission yeast primase catalytic subunit in the replication checkpoint. Mol. Biol. Cell 12:115-128.
127. De Silva FS, Lewis W, Berglund P, Koonin EV, Moss B. 2007. Poxvirus DNA primase. Proc. Natl. Acad. Sci. U. S. A. 104:18724-18729.